# Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal Cancer

> **NCT02982694** · PHASE2 · TERMINATED · sponsor: **Vall d'Hebron Institute of Oncology** · enrollment: 46 (actual)

## Conditions studied

- MSI
- ColoRectal Cancer
- Chemotherapy
- Resistance, APC

## Interventions

- **DRUG:** Atezolizumab
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT02982694
- **Lead sponsor:** Vall d'Hebron Institute of Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-11-24
- **Primary completion:** 2020-11-27
- **Final completion:** 2020-11-27
- **Target enrollment:** 46 (ACTUAL)
- **Why stopped:** The results of the interim analysis showed that the efficacy in the MSS subgroup (MSI like) is inferior to the expected, and this situation is very unlikely to be reversed if the trial is fully completed.
- **Last updated:** 2025-10-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02982694

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02982694, "Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02982694. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*